Back to results
US 12,747,215 B2Granted
N2-arylmethyl-4-haloalkyl-pyridazin-3-one CFTR modulators for the treatment of cystic fibrosis
AssigneesUniversite de Reims Champagne-Adrenne Reims (FR), Inserm (Institut National De La Sante Et De La Recherche Medicale), Universite De Rouen Normandie, Centre National de la Recherche Scientifique (CNRS)
InventorsStéphane Gerard, Jean-Philippe Bouillon, Abderrazzaq Bentaher, Eric Henon, Jacky Jacquot, Janos Sapi, Frédéric Velard
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of Formula I: or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, in particular cystic fibrosis.
Claims9
A compound of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof,
- wherein:
- R1 is cyclohexyl, thiophenyl, pyridinyl or phenyl, optionally substituted by a group selected from C1 to C4 alkyl, C1 to C2 alkoxy and C1 to C2 arylalkyl;
- R2 is H or alkyl;
- R3 is cycloalkyl, heteroaryl or aryl, optionally substituted by one or two groups selected independently from alkyl, alkoxy and haloalkoxy;
- R4 is H;
- RF is C1 to C6 haloalkyl;
- and
- is a single bond or a double bond.
6 more elements
Dependencies are inferred from the claim text.